



(51) International Patent Classification:

A61K 31/315 (2006.01) A61P 29/00 (2006.01)
A61P 3/10 (2006.01) A61P 37/08 (2006.01)
A61P 11/02 (2006.01)

(21) International Application Number:

PCT/IB2024/054991

(22) International Filing Date:

22 May 2024 (22.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/468,018 22 May 2023 (22.05.2023) US

(72) Inventors; and

(71) Applicants: VINOKUR, Vladimir [IL/IL]; 8 Zipornit Street, 7171523 Modiin (IL). CHEVION, Dror [IL/IL]; 18 Hayahalom Street, 4061818 Tel Mond (IL). ANGEL, Itzhak [IL/IL]; 22 Lotus Street, 7404578 Nes Ziona (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL COMPOSITION FOR TREATMENT OF INFLAMMATORY RELATED DISORDERS




Fig. 1

(57) Abstract: Disclosed herein are to compositions comprising complexes of deferoxamine (such as DFO B) with at least one metal, such as with Zn^{2+} or Ga^{3+} or silver or gold or any combinations thereof, and a hydrophilic, non-ionic surfactant comprising polyethylene glycol (PEG) and a non-ionic triblock copolymer comprising poloxamers. The surfactant may further comprise nonionic triblock copolymers are composed of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)). Also disclosed are procedures for the preparation of the complexes and pharmaceutical compositions comprising said complexes or any combinations of said complexes, as well as methods using the disclosed compositions and complexes in modulating cytokine levels in a subject and thereby treating inflammation-associated disorders.

[Continued on next page]

(88) Date of publication of the international search report:
02 January 2025 (02.01.2025)